Galmed Pharmaceuticals Ltd - Asset Resilience Ratio
Galmed Pharmaceuticals Ltd (GLMD) has an Asset Resilience Ratio of 76.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Galmed Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Check Galmed Pharmaceuticals Ltd (GLMD) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Galmed Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Galmed Pharmaceuticals Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $14.17 Million | 76.08% |
| Total Liquid Assets | $14.17 Million | 76.08% |
Asset Resilience Insights
- Very High Liquidity: Galmed Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 76.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Galmed Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Galmed Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Galmed Pharmaceuticals Ltd (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Galmed Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 76.08% | $14.17 Million | $18.63 Million | +18.35pp |
| 2024-12-31 | 57.72% | $10.68 Million | $18.50 Million | -1.09pp |
| 2023-12-31 | 58.82% | $9.78 Million | $16.63 Million | -12.25pp |
| 2022-12-31 | 71.06% | $11.77 Million | $16.56 Million | -16.17pp |
| 2021-12-31 | 87.23% | $31.93 Million | $36.60 Million | +3.35pp |
| 2020-12-31 | 83.88% | $43.94 Million | $52.38 Million | +6.67pp |
| 2019-12-31 | 77.21% | $59.56 Million | $77.14 Million | +4.33pp |
| 2018-12-31 | 72.88% | $66.03 Million | $90.60 Million | +42.46pp |
| 2017-12-31 | 30.42% | $5.98 Million | $19.64 Million | -44.66pp |
| 2016-12-31 | 75.08% | $12.35 Million | $16.45 Million | -2.59pp |
| 2015-12-31 | 77.67% | $18.84 Million | $24.26 Million | +52.61pp |
| 2014-12-31 | 25.06% | $8.25 Million | $32.92 Million | -- |
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have… Read more